Science News
from research organizations

New therapeutic target identified for deadly thyroid carcinomas

Date:
October 16, 2013
Source:
American Thyroid Association
Summary:
A novel drug target, and evidence of the strong anti-tumor effects of an inhibitor capable of blocking expression of the target are described in new research.
Share:
         
Total shares:  
FULL STORY

Anaplastic thyroid carcinomas (ATC) are aggressive tumors that do not respond to traditional radio- or chemotherapeutic agents, and there currently is no cure or effective treatment available. Median survival from diagnosis is 5 months, and although ATC accounts for only 1.7% of all thyroid cancers in the U.S., it is responsible for a large proportion of thyroid cancer-related deaths. A novel drug target, and evidence of the strong anti-tumor effects of an inhibitor capable of blocking expression of the target are described in a poster to be presented at the 83rd Annual Meeting of the American Thyroid Association, October 16-20, 2013, in San Juan, Puerto Rico.

Christina von Roemeling and colleagues from The Mayo Clinic, Jacksonville, FL, found that the enzyme stearoyl-CoA desaturase 1 (SCD1), which has a role in fatty acid metabolism, is expressed at high levels in tissue samples from patients with papillary thyroid carcinoma (PTC), high grade follicular thyroid carcinoma (FTC), and ATC. An inhibitor of SCD1 expression demonstrated strong anti-tumor activity--reduced tumor cell proliferation and increased cell death--specifically in ATC cells and showed little to no activity in PTC or FTC cells. The sequential addition of a proteasome inhibitor led to a synergistic effect and enhanced anti-tumor activity in ATC cells. The researchers propose the combined use of an SCD1 inhibitor and a proteasome inhibitor as a new treatment regimen that might benefit patients with ATC.

"Since anaplastic thyroid cancer is one of the most aggressive and least treatable of all cancers, new therapies are desperately needed," says Ronald J. Koenig, M.D., Ph.D, Program Committee Co-Chair, and Professor, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor. "The study by von Roemeling and colleagues is important because they show that drugs that inhibit the enzyme SCD1 can kill anaplastic thyroid cancer cells in a culture dish. This exciting finding will need to be tested in animal models of anaplastic thyroid cancer before consideration of clinical trials, but it offers hope for a disease very much in need of new therapies."


Story Source:

The above story is based on materials provided by American Thyroid Association. Note: Materials may be edited for content and length.


Cite This Page:

American Thyroid Association. "New therapeutic target identified for deadly thyroid carcinomas." ScienceDaily. ScienceDaily, 16 October 2013. <www.sciencedaily.com/releases/2013/10/131016095845.htm>.
American Thyroid Association. (2013, October 16). New therapeutic target identified for deadly thyroid carcinomas. ScienceDaily. Retrieved May 4, 2015 from www.sciencedaily.com/releases/2013/10/131016095845.htm
American Thyroid Association. "New therapeutic target identified for deadly thyroid carcinomas." ScienceDaily. www.sciencedaily.com/releases/2013/10/131016095845.htm (accessed May 4, 2015).

Share This Page:


Recommended Content
 


Health & Medicine News
May 4, 2015

Latest Headlines
updated 12:56 pm ET